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A B S T R A C T   
Paclitaxel is an anti-microtubule agent, most widely used chemotherapeutic agent for the treatment of malignant 
solid tumors. However, it is associated with some severe side effects including painful neurotoxicity with 
reporting of neuropathic pain and sensory abnormalities by patients during and after paclitaxel therapy. Pe-
ripheral neuropathy was induced by the administration of paclitaxel (4 mg/kg on days 1, 3, 5, and 7). In this 
study, the anti-nociceptive and anti-inflammatory propensity of 3-Hydroxyflavone (3HF) in mice and the pre-
ventive effect of 3HF against paclitaxel-induced peripheral neuropathy in Sprague Dawley (SD) rats were 
investigated. Moreover, tactile and cold allodynia, thermal and tail immersion hyperalgesia, and effects on 
motor-coordination were also evaluated. Furthermore, the expression of proinflammatory cytokines i.e. Calci-
tonin gene-related peptide (CGRP), and Substance P from the spinal cord was examined through RT-PCR. 
Additionally, a computational structural biology approach was applied to search the potential therapeutic tar-
gets and to predict the binding mechanism of 3HF. 
Treatment of 3HF alleviated the nociceptive pain, paw edema, development of tactile and cold allodynia, and 
hyperalgesia. Similarly, treatment with 3HF suppressed the paclitaxel-induced increase in mRNA expression of 
several inflammatory cytokines including tumor necrosis factor -α (TNF-α), interleukin-1β (IL-1β), and 
interleukin-6 (IL-6), CGRP, and Substance P. However, the daily treatment of 3HF did not affect the motor 
behaviors of rats. The inhibitory mechanism of 3HF in neuropathic pain is predicted with extensive computa-
tional bioinformatics approach which indicates that the 3HF effectively interacts with the binding domains of 
Nuclear factor-kappa B (NF-κB), CGRP receptor and the receptor of Substance P to exert its inhibitory activities. 
However, the computationally predicted binding affinities revealed that the potential of binding of the com-
pound with Substance P receptor (Neurokinin 1 receptor) is higher than the other receptors; there NK1R could be 
the most possible binding target of 3HF. These findings indicate that 3HF has anti-nociceptive, anti-inflamma-
tory, and anti-neuropathic pain effects against paclitaxel-induced neuropathic pain.   
1. Introduction 
Neuropathic pain is a chronic pathological pain, caused by functional 
and structural damage of the sensory nervous system (Akbar et al., 
2016). It is characterized by hypersensitivity to noxious (hyperalgesia) 
and non-noxious (allodynia) stimulation (Sałat, 2020). Numerous 
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studies have revealed that peripheral nerve injury produces heteroge-
neous, prolongs pain conditions called neuropathic pain (Khan et al., 
2016). Chronic neuroinflammation in peripheral and central nervous 
systems plays a vital role in the cause and maintenance of neuropathic 
pain (Hughes et al., 2012). However, in several animal models of 
neuropathic pain, the elevated level of inflammatory cytokines have 
been observed in injured tissues like dorsal root ganglion (DRG), spinal 
cord, and brain regions responsible for the propagation of pain (Lees 
et al., 2013; Vickers, 2017). Inflammatory mediators such as IL-1β, IL-6, 
and TNF-α are stimulated through the activation of a transcription factor 
called nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-κB) (Naveed et al., 2019), which decreases the threshold of pain by 
sensitizing nociceptors directly (Sandkuhler, 2009). Moreover, several 
neuropeptides (Substance P, calcitonin gene-related peptide) are 
released within the dorsal horn and play a pivotal role in pain regulating 
responses (Chen et al., 2015). 
Neuropathy is initiated from nerve damage including HIV neuropa-
thy, diabetic-induced neuropathy, drug-induced neuropathy, post-
herpetic neuralgia, and traumatic nerve injury (Khan et al., 2016). 
Neuropathic pain syndrome is associated with many first-line chemo-
therapeutic agents (Onodera et al., 2013). Paclitaxel is the preferred 
chemotherapy agent for solid tumor treatment in clinical practices 
(Gordon et al., 2011). However, it is associated with long lasting and 
dose-limiting side effect like peripheral neuropathy (Manjavachi et al., 
2019). Paclitaxel-induced neuropathy is characterized by hypersensi-
tivity to cold and mechanical stimuli that occur early at the treatment 
initiation (Fu and Gordon, 1997). Spinal cord inflammation plays 
important role in chemotherapy-induced peripheral neuropathy, with 
released of pro-inflammatory chemokines contributing to central 
sensitization (Manjavachi et al., 2019). Likewise, such inflammatory 
mediators releases in the peripheral nervous system following chemo-
therapy, due to activation of glial cell and the mononuclear leukocytes 
infiltration into the dorsal root ganglions (DRG), contributes to the 
enhancement of neuronal excitability (Liu et al., 2014; Warwick and 
Hanani, 2013). 
Paclitaxel-induced peripheral neuropathy is one of the chemother-
apeutic agent-induced peripheral neuropathy (CIPN), used to develop 
animal models to understand the mechanism of neuropathic behaviors 
and for the design and discovery of new anti-neuropathic agents (Khan 
et al., 2016; Zhang et al., 2019). Neuropathy is a dose-limiting adverse 
effect of chemotherapy. Paclitaxel-induced neuropathic pain is one of 
the most frequently seen neuropathic pain in the clinic and is observed 
in up to 80% of patients treated with paclitaxel (Sisignano et al., 2014). 
There is no safe and effective therapy available for the treatment of this 
painful condition (Zhang et al., 2019). 
The available therapy for chronic neuropathic pain management 
includes anti-depressants, opioids, and anti-epileptics, however due to 
their severe adverse effects, their use in attenuation of peripheral neu-
ropathy is limited (Sisignano et al., 2014). Therefore, effective alterna-
tive therapy with the promising effect is instantly required for the 
treatment of neuropathic pain. 
Flavonoids are beneficial for human health and present in a variety 
of plants, dietary substances, and in the synthetically produced form 
(Tapas et al., 2008). Flavonoids have shown potent anti-oxidant, anti--
inflammatory, anxiolytic, anti-nociceptive, neuroprotective, and 
anti-neuropathic properties. Moreover, flavonoids interact with various 
neurotransmitter systems (GABA, serotonin, dopamine, glycine) 
involved in neuroprotection and neuronal activity modulation (Shahid 
et al., 2017b). In this regard, the neuroprotective effect of 3HF in 
paclitaxel-induced neuropathic pain animal model was evaluated along 
with tactile and cold allodynia, thermal and tail immersion hyper-
algesia, and effects on motor-coordination. Additionally, attempts were 
made to investigate the potential mechanisms of neuroprotective effect 
and anti-neuropathic properties of 3-Hydroxyflavone, for this purpose, 
the expression of proinflammatory cytokines, CGRP, and Substance P 
were examined in the spinal cord through RT-PCR. Furthermore, 
computational structural biology was employed to predict the binding 
mechanism of 3HF. 
2. Materials and methods 
2.1. Chemicals and reagents 
3HF and Naloxone (Sigma, USA), Paclitaxel (Alfa Aesar, Thermo 
Fisher Scientific, Germany), dimethyl sulfoxide (DMSO, Unichem, USA), 
Tween-80 (80%, Scharlau, Spain), TRI-reagent (Bioshop, Canad), cDNA 
synthesis kit (abm, Canada), PCR master mix (Thermo Fisher Scientific, 
Germany), PCR primers (Macrogen Korea), DNA ladder (Invitrogen US) 
agarose, Boric acid and ethidium bromide (Sigma-Aldrich USA) were 
used. 3HF was dissolved in a vehicle containing normal saline, DMSO, 
and Tween-80 in a ratio of 95:04:01. 
2.2. Animals 
Sprague-Dawley male rats (SD, 200–250 g) and Albino mice (18–30 
g) were bred and maintained at 22.0 ± 2.0 ◦C with 12/12 h light/dark 
cycle in the animal house of the Department of Pharmacy, University of 
Peshawar, Pakistan. The experimental procedures were approved by the 
departmental ethical committee of the University of Peshawar 
(Approval no. 12/EC-17/Pharm) and were performed under the rules of 
the UK Animals (Scientific Procedures) Act 1986. All experiments were 
carried out during day time (8:0 a.m. to 4:0 p.m.). The schedule for 
experiments using mice and rats are shown in Fig. 1. 
2.3. Anti-nociceptive activities 
To evaluate the peripheral and central anti-nociceptive activities of 
3HF in mice (18–22 g); Acetic-acid induced writhing and hotplate test 
were used (Rukh et al., 2020; Subhan et al., 2010). The antagonistic 
effect of Naloxone on the anti-nociceptive activity of 3HF using a hot 
plate model was also investigated in mice. 
2.3.1. Acetic acid-induced writhes 
Writhing test is a chemical method of pain induction of peripheral 
origin by injection of irritant like acetic acid in mice. The decrease in the 
writhing frequency indicted analgesic activity of the test compound 
(Gawade, 2012). Mice were deprived of food for 2 h before the start of 
any experiment. The animals were divided into five groups including; 
vehicle 10 ml/kg (Group I), a standard analgesic Diclofenac 50 mg/kg 
(Group II), and test drug 3HF of three different doses (25, 50, and 75 
mg/kg) (Group III, IV, V). All mice were administered intraperitoneally 
30 min before the injection of 10 ml/kg acetic acid (1%). The number of 
writhes (abdominal contraction) induced by acetic acid was measured 
for 20 min (Subhan et al., 2010). The percent-antinociceptive effect was 
calculated from the number of writhes as; [%-Inhibition = 1 – test/ve-
hicle) × 100]. 
2.3.2. Hot plate activity 
It is used for the evaluation of the central anti-nociceptive potential 
of drug (Brochet et al., 1986). The anti-nociceptive effect of the test drug 
was tested in mice using a hot plate analgesiometer maintained at 54.0 
± 0.10◦. The animals were divided into 5 groups including; vehicle 10 
ml/kg (Group I), a standard analgesic Tramadol 30 mg/kg (Group II), 
and test drug 3HF of three different doses (25, 50, and 75 mg/kg) (Group 
III, IV, V). The vehicle, tramadol, and 3HF were injected intraperito-
neally, the latency time in seconds of animal’s withdrawal responses on 
the hot plate was noted at intervals of 30, 60, and 90 min. The %-anti-
nociceptive activity was calculated from the latencies as; 
[%-Protection=(test – baseline)/(cut-off – baseline) × 100] (Rukh et al., 
2020). 
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2.3.3. Effect of naloxone on anti-noceciptive activity of 3HF on hot plate 
model 
To evaluate the antagonistic effect of Naloxone against 3HF, the 
animals were divided into ten groups (n = 6/group). All the animals 
were kept fasting for 2 h before the start of the experiment (Subhan 
et al., 2010). Drugs were administered intraperitoneally to all animals 
(Table 1), and the latency times were recorded at 30, 60, and 90 min 
intervals after drug administration. The Naloxone was administered 
subcutaneously 10 min prior to the vehicle, tramadol, and 3HF 
administration (Ahmad et al., 2017a). 
2.4. Anti-inflammatory activities 
Carrageenan, histamine, and serotonin-induced paw edema tests are 
used for the evaluation of anti-inflammatory drugs. Paw edema devel-
oped by carrageenan is a biphasic event. The release of cytokines, 
bradykinin, histamine, and serotonin occurs in the initial phase of 
edema. While the release of prostaglandins take place in the second 
phase of edema (Rodrigues et al., 2016; Vasudevan et al., 2007). His-
tamine and serotonin are important inflammatory mediators, they cause 
vasodilation and enhanced vascular permeability (Cuman et al., 2001; 
Linardi et al., 2000). 
The anti-inflammatory efficacy of 3HF was studied using the mouse 
models of carrageenan (Munir et al., 2020; Winter et al., 1962), hista-
mine (Naveed et al., 2019; Singh et al., 1996), and serotonin (Cole et al., 
1995; Rukh et al., 2020) induced paw edema tests. The animals were 
administered with vehicle, diclofenac (50 mg/kg, i. p.), chlorphenir-
amine (10 mg/kg, i. p.), mianserin (1 mg/kg, s. c.), and 3HF at doses of 
25, 50, and 75 mg/kg (i.p.). The phlogistic agents were injected into the 
subplantar region and the edema was measured at 1, 3, 5 h after 
administration of phlogestic agents using a digital plethysmometer. In 
each inflammation paradigm, the change in edema was determined (Δ 
= post-dose paw volume – baseline paw volume) and the 
anti-inflammatory response in percent was calculated as [%-inhibition =
(1 – Δ test/Δ vehicle) × 100]. 
2.5. Induction of neuropathic pain and drug administration 
Paclitaxel is natural anti-cancer drug; causes chemotherapy-induced 
peripheral neuropathy, which adversely affects the treatment course and 
quality of the patients (YAŞAR et al., 2020). Male SD rats were injected 
intraperitoneally (i.p.) Paclitaxel (4 mg/kg) or vehicle four times a week 
(on days 1, 3, 5, and 7). 3HF was injected (i.p.) once a day for seven 
days. Behavioral experiments were performed before drug administra-
tion and on days 2, 4, 6, and 8. Animals were sacrificed on day 8 for 
Fig. 1. Schedule for experiments.  
Table 1 
Grouping of animals.  
Groups Drugs administered intraperitoneally 
Group 1 Vehicle (10 ml/kg) 
Group 2 Vehicle (10 ml/kg) + naloxone (1 mg/kg) 
Group 3 Tramadol (30 mg/kg) 
Group 4 Tramadol (30 mg/kg) + naloxone (1 mg/kg) 
Group 5 3HF (25 mg/kg) 
Group 6 3HF (25 mg/kg) + naloxone (1 mg/kg) 
Group 7 3HF (50 mg/kg) 
Group 8 3HF (50 mg/kg) + naloxone (1 mg/kg) 
Group 9 3HF (75 mg/kg) 
Group 10 3HF (75 mg/kg) + naloxone (1 mg/kg)  
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sample collection (Tsutsumi et al., 2016). The animals were distributed 
randomly in the following groups (n = 8). 
Group I: Vehicle. 
Group II: Paclitaxel (4 mg/kg, 4 times/week, i. p) + Vehicle. 
Group III: Paclitaxel (4 mg/kg, 4 times/week, i. p) + Gabapentin 75 
mg/kg (once daily for 7 days i. p). 
Group IV: Paclitaxel (4 mg/kg, 4 times/week, i. p) + 3HF 25 mg/kg 
(once daily for 7 days i. p). 
Group V: Paclitaxel (4 mg/kg, 4 times/week, i. p) + 3HF 50 mg/kg 
(once daily for 7 days i. p). 
Group VI: Paclitaxel (4 mg/kg, 4 times/week, i. p) + 3HF 75 mg/kg 
(once daily for 7 days i. p). 
2.5.1. Behavioral experiments 
2.5.1.1. Evaluation of tactile allodynia in paclitaxel-induced rats. 
Tactile allodynia was assessed before first drug administration and on 
days 2, 4, 6, and 8, using a series of von Frey filaments (15, 8, 6, 4, 2, 1.4, 
1, 0.6, and 0.4 g) (Touch Test® Sensory Evaluators, North Coast, USA), 
were applied to the mid plantar area of the hind paw of rats perpen-
dicularly, to an extent that caused the filament to bend. Each filament 
was applied for 6 s (cut off time) or until withdrawal response (lifting of 
paw, licking, or flinching) displayed by the animal. The force 15 g was 
considered as a cutoff force. To evade any influence of former stimuli on 
rat behavior, the filaments were applied at intervals of several seconds. 
The stimulus was repeated in case of an indefinite response. The paw 
withdrawal threshold (PWT) in both hind-paws was measured with a 5 
min interval and the mean value of three readings was calculated (Ali 
et al., 2015). 
2.5.1.2. Evaluation of cold allodynia (acetone test). Animals were 
habituated for 30 min by placing underneath the inverted transparent 
box on the shelf with a meshed wire floor. After habituation, 0.05 mL 
acetone was applied 3 times alternatively to the mid-plantar surface of 
each hind paw at 30 s of the interval using one C.C syringe, and the 
duration of paw withdrawal of response (PWD) (liking, biting or 
flinching) was recorded. 
This test was performed by gently touching the mid-plantar skin of 
the hind paws with 50 μL acetone. Prior to this test, animals were 
habituated for 30 min in a transparent box on a shelf with a meshed wire 
floor. After habituation, 0.05 mL acetone was applied 3 times alterna-
tively to the mid-plantar surface of each hind paw at 30 s of the interval 
using one C.C syringe, and the duration of paw withdrawal response 
(PWD) (liking, biting, or flinching) was recorded (Shahid et al., 2017a). 
2.5.1.3. Evaluation of thermal hyperalgesia. Thermal hyperalgesia test 
was performed using hot-plate (Harvard apparatus, USA), maintained at 
52.0 ± 0.20 ◦C. The animals were kept on the hot plate and response 
latency time (sec) was recorded either by jumping or lifting/licking of 
hind-paws. To avoid tissue damage, 1 min was adopted as a cut-off time. 
The response latency time was assessed before the first drug adminis-
tration and on days 2, 4, 6, and 8. The response latency of each rat was 
measured in triplicate and the average value from 3 readings was taken 
as nociceptive response latency (Ahmad et al., 2017b). 
2.5.1.4. Hot water tail immersion test. To assess the central anti- 
nociceptive activity of 3HF, tail immersion test in hot water was car-
ried out. Briefly, the tip of the rat tail was immersed in hot water (46 ◦C), 
until withdrawal of tail occurred. The tail immersion duration was 
recorded with 15 s cutoff time. Each rat was subjected to three trials with 
5 min interval and average value was calculated. Test was performed 
before any drug treatment and post drug treatment on days 2, 4, 6, and 8 
(Authier et al., 2003). 
2.5.1.5. Cold water tail immersion test. Tail cold-allodynia was assessed 
by dipping the tail tip in ice-cold water (4 ◦C) and tail withdrawal la-
tency (TWL) in seconds to withdrawal reflexes was recorded. To prevent 
tissue damage, a cut-off time of 15 s was imposed. The test was per-
formed three times for each rat and average of three measurements was 
calculated. Furthermore, test was carried out prior to first drug admin-
istration and on days 2, 4, 6, and 8. Normal animals respond rarely 
within 15 s, while neuropathic animals respond frequently (Polomano 
et al., 2001). 
2.5.1.6. Effects of 3HF on muscle strength and motor activity. Rotarod test 
was carried out to assess the effect of 3HF on motor coordination. Rats 
were placed on the rotarod, rotating with the increasing speed (4–40 
rotations per minute) over 5 min; animals were forced to move forward 
to prevent falling off. The falling off time of animals fell from rotating- 
device was noted. The effect on motor-performance was assessed prior 
to first drug administration and on days 2, 4, 6, and 8 (Shahid et al., 
2017a). 
2.5.2. Reverse transcriptase polymerase chain reaction 
Total RNA was extracted from the spinal cord (L4-L6) segments using 
TRI-reagent according to the manufacturer’s instructions. The purity of 
RNA was confirmed using UV-spectrophotometer. RNA was converted to 
cDNA through a cDNA synthesis kit. The PCR primers (TNF-α, IL-1β, IL- 
6, CGRP, and Substance P) are listed in Table 2 β-actin was used as an 
internal control. Agarose gel (1.5%) was used for amplified product 
separation. The mRNA expression was calculated in the arbitrary unit 
using ImageJ software (Ullah et al., 2020). 
2.5.3. Molecular modeling 
The molecular targets of 3HF were searched through a literature 
survey (Ahmed et al., 2019). The binding affinity of 3-hydroxy flavone 
with the selected targets was predicted by the molecular docking 
approach. Docking was carried out on Molecular Operating Environ-
ment (MOE v 2009.14). The three-dimensional structures of selected 
targets (Nuclear factor κB (PDB code: 1NFK), Substance P Receptor 
(Neurokinin 1 receptor, PDB code: 6HLP) and Calcitonin Gene-Related 
Peptide Receptor, PDB code: 6E3Y) were downloaded from RCSB Pro-
tein Databank (RCSB-PDB, https://www.rcsb.org/). Hydrogen was 
added and partial charges were applied on proteins based on Amber 12: 
EHT force field of MOE. The heteroatoms other than ligands were 
removed. Similarly, water molecules within the vicinity of 3 Å of the 
binding site were retained, while the rest of the water molecules were 
removed from protein structures. The PDB structures were then used in 
the molecular docking using the Triangle Matcher docking method and 
London dG scoring function of MOE. For docking, induce fit docking 
protocol was applied in order to assess the receptor conformational 
flexibility during docking. The 3D-structure of 3HF was built and 
minimized on MOE with MMFF94× force field with gradient = 0.1 RMS 
kcal/mol/Å with default parameters (eps = r, cutoff). 
Table 2 
Primers sequences for PCR reaction are shown in table.  
Primer Sequence 





reverse, 5′- TCCATTGAGGTG- GAG AGCTT-3′
IL-6 forward, 5′-GGAGTTTGTGAAGAACAACT-3′
reverse, 5′-CTAGGGTTTCAGTATTGCTC-3′
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2.6. Statistical analysis 
One-way or two-way ANOVA tests were used for statistical analysis, 
followed by Dunnett’s posthoc or bonferroni test, using GraphPad prism 
software. A P-value of ≤0.05 was considered statistically significant. 
3. Results 
3.1. Evaluation of anti-nociceptive activities of 3HF 
3.1.1. Acetic acid-induced writhing model 
In this study, we found a significant decline in the number of acetic- 
acid induced writhes, which indicate an increased %-inhibition of pain 
in mice treated with diclofenac at a dose of 50 mg/kg (***p < 0.001), 
3HF at doses of 25 mg/kg (*p < 0.05), 50 mg/kg (**p < 0.01), and 75 
mg/kg (***p < 0.001) as compared to the vehicle-treated mice (Fig. 2). 
3.1.2. Hot plate test 
Mice treated with Tramadol (30 mg/kg) and 3HF (75 mg/kg) 
exhibited a significant increase in protection (%) from pain induced by 
thermal stimuli at 30, 60, and 90 min intervals (***p < 0.001). Likewise 
the 3HF at doses of 25 and 50 mg/kg also showed significant percent 
protection from pain at all intervals (*p < 0.05, **p < 0.01) (Fig. 3). 
3.1.3. Effect of naloxone on the anti-nociceptive potential of 3HF using hot 
plate model 
The antagonizing effect of Naloxone on Tramadol and 3HF’s anal-
gesic activities in mice were investigated in the hotplate test. Results 
have shown in Fig. 4 that the Naloxone (1 mg/kg) antagonized the anti- 
nociceptive potential of Tramadol and 3HF significantly (*p < 0.05, **p 
< 0.01, ***p < 0.001) at 30–90 min intervals. 
3.2. Anti-inflammatory activity of 3HF 
In the carrageenan-induced paw edema test, 3HF attenuated exag-
geration in paw-edema at concentrations of 25, 50, and 75 mg/kg, 
observed at 1 h (P < 0.05, P < 0.001), 3 h (P < 0.05, P < 0.01, P < 
0.001), and 5 h (P < 0.01) after carrageenan administration. However, 
the standard drug diclofenac (50 mg/kg) was effective in mitigating the 
escalation of inflammation associated with carrageenan (P < 0.001) 
(Table 3). 
In the histamine-induced paw edema test, 3HF reduced inflamma-
tion at tested doses for 1–5 h experiment (P < 0.05, P < 0.01, P < 
0.001). At the dose of 25 mg/kg, 3HF alleviate paw edema for 1–3 h 
more efficiently (P < 0.05). Similarly, 3HF at doses of 50 and 75 mg/kg, 
effectively reduced paw edema volume during 1–5 h experiment 
significantly (P < 0.01, P < 0.001). Chlorpheniramine (10 mg/kg) was 
used as a standard drug, reduced paw edema volume at 1, 3, and 5 h 
Fig. 2. Analgesic activities of 3HF mice using acetic acid-induced writhing model. The data were expressed as percent inhibition means ± SEM (n = 6). Data were 
analyzed by one-way ANOVA followed by the Dunnett post hoc test. *p < 0.05, **p < 0.01, and ***p < 0.001 indicate statistical significance in comparison with the 
vehicle-treated group. 
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intervals significantly (P < 0.001) (Table 3). 
In the serotonin-induced paw edema test, 3HF was effective at doses 
of 25–75 mg/kg in the inhibition of serotonin-induced inflammation 
during 1–5 h experiment (P < 0.05, P < 0.01, P < 0.001). Mianserin (1 
mg/kg) was used as a standard drug, reduced paw edema at all intervals 
significantly (P < 0.001) (Table 3). 
3.3. Effects of 3HF on tactile allodynia 
The neuropathic allodynia was produced by intraperitoneal admin-
istration of paclitaxel at a dose of 4 mg/kg for 4 alternate days, reduced 
paw withdrawal threshold (PWT) on days 4, 6, and 8 significantly as 
compared to vehicle-treated group (P < 0.01, P < 0.001). The paclitaxel- 
induced allodynia was significantly reduced by 3HF treatment [time=
(F (4, 90) = 18.6, P < 0.0001, treatment= (F (5, 90) = 30.5, P < 0.0001, 
interaction= (F (20, 90) = 4.32, P < 0.0001)]. Treatment with the 3HF 
at a dose of 25 mg/kg showed a significant increase in PWT (P < 0.05) 
on day 8. Whereas at the dose of 50 mg/kg increased the PWT on days 6 
and 8 significantly (P < 0.01). Moreover, 3HF (75 mg/kg) inhibited the 
reduction in the withdrawal-threshold on days 6 and 8 (P < 0.001). The 
standard Gabapentine displayed a significant increase in threshold (P < 
0.0001) (Fig. 5). 
3.4. Effects of 3HF on cold allodynia 
Cold allodynia was induced in rats after repeated administration of 
paclitaxel, exhibited increase paw withdrawal duration (PWD) in com-
parison with vehicle-treated group (P < 0.0001). Treatment with 3HF 
significantly reduced the paclitaxel-induced cold allodynia in rats 
[time= (F (4, 90) = 39.7, P < 0.0001, treatment= (F (5, 90) = 42.5, P < 
0.0001, interaction= (F (20, 90) = 3.88, P < 0.0001)]. The 3HF (25 mg/ 
kg) treated group exhibited a significant decrease in PWD (P < 0.05) on 
day 8. The 3HF at the dose of 50 mg/kg caused a significant decrease in 
PWD on days 4, 6, and 8 (P < 0.05, P < 0.01, P < 0.001). While, 3HF 
(75 mg/kg) treated group displayed a significant decline in PWD (P < 
0.05, P < 0.001). Likewise, the standard Gabapentine exhibited a sig-
nificant decrease in PWD (P < 0.0001) (Fig. 6). 
3.5. Effects of 3HF on thermal hyperalgesia 
Repeated Paclitaxel administration caused significant changes in 
thermal nociceptive perception, indicated by decreased paw withdrawal 
latency (PWL) in paclitaxel treated group as compared to vehicle-treated 
group (P < 0.05, P < 0.01). The paclitaxel therapy associated thermal 
hyperalgesia was significantly reduced by 3HF treatment [time= (F (4, 
60) = 3.75, P < 0.0087, treatment= (F (5, 60) = 8.39, P < 0.0001, 
interaction= (F (20, 60) = 1.14, P < 0.3360)]. Treatment with 3HF 
Fig. 3. Effect of 3HF at doses of 25, 50, and 75 mg/kg on thermally induced nociception in mice in Hot plate test. Data were analyzed by one-way ANOVA followed 
by Dunnett posthoc. The bar expressed percent protection means ± SEM (n = 6). *p < 0.05, **p < 0.01, and ***p < 0.001 indicates statistical significance in 
comparison with the vehicle-treated group. 
R. Ullah et al.                                                                                                                                                                                                                                   
Neurochemistry International 144 (2021) 104981
7
ameliorated the neuropathic thermal hyperalgesia significantly (P < 
0.05, P < 0.01) as compared to paclitaxel-treated group (Fig. 7). 
3.6. Effects of 3HF on tail hyperalgesia 
The anti-nociceptive tail immersion test was performed to observe 
the tail withdrawal response latency (TWL). Tail withdrawal reflexes 
indicate central nociception. Animals treated with paclitaxel showed a 
decrease in TWL as compared to the control group (P < 0.05, P < 0.01, 
P < 0.001). The 3HF (25–75 mg/kg) and gabapentine treatment pro-
longed the TWL (P < 0.05, P < 0.01, P < 0.001) (Fig. 8). 
3.7. Effects of 3HF on tail cold hyperalgesia 
To assess the cold anti-hyperalgesia properties of 3HF, tail immer-
sion test in cold water was performed. Paclitaxel-treated rats showed a 
decrease in TWL as compared to the vehicle-treated group, indicating 
enhanced cold hyperalgesia in rats. 3HF treated animals exhibited an 
increase in TWL dose-dependently as compared to vehicle-treated ani-
mals (P < 0.05, P < 0.01, P < 0.001), indicating the protective effect of 
3HF against cold hyperalgesia. Likewise, Gabapentine also displayed an 
increase in TWL (P < 0.001) (Fig. 9). 
3.8. Effects of 3HF on motor activity of animals 
Rotarod test was performed to assess the undesirable effects of drug 
Fig. 4. The effect of Naloxone (NLX) on the anti-nociceptive activity of 3HF in mice tested on the hot plate at 30, 60, and 90 min intervals. Data were analyzed by 
two-way ANOVA followed by the Bonferroni test. *p < 0.05, **p < 0.01, and ***p < 0.001 compared to their respective control group. Values were expressed as 
%-protection means ± SEM (n = 6). 
Table 3 
Effect of 3-hydroxy flavone (3HF) on phlogestic agents induced inflammation.  
Phlogestic agent Treatment Dose 1 h 3 h 5 h 
Inhibitions (%) Inhibitions (%) Inhibitions (%) 
Carrageenan Vehicle + Carrag 10 ml/kg 12.24 ± 3.890 9.97 ± 2.572 09.58 ± 4.932 
Diclofenac + Carrag 50 mg/kg 77.53 ± 7.731*** 64.23 ± 5.084*** 55.56 ± 7.094*** 
3HF + Carrag 25 mg/kg 50.73 ± 9.652** 39.35 ± 8.926* 28.08 ± 10.876  
50 mg/kg 63.25 ± 8.324*** 52.78 ± 5.768** 43.06 ± 5.765**  
75 mg/kg 72.65 ± 5.649*** 63.09 ± 4.089*** 50.84 ± 9.087** 
Histamine Vehicle + His 10 ml/kg 08.37 ± 4.251 06.08 ± 2.875 07.83 ± 1.705 
Chlorphinarmin + His 10 mg/kg 79.95 ± 6.984*** 62.50 ± 7.409*** 53.75 ± 6.914*** 
3HF + His 25 mg/kg 45.43 ± 7.309** 35.79 ± 5.907* 26.05 ± 4.359  
50 mg/kg 57.32 ± 8.237*** 44.95 ± 7.946** 35.06 ± 6.901**  
75 mg/kg 69.82 ± 3.594*** 58.15 ± 8.965*** 45.98 ± 3.802** 
Serotonin Vehicle + Ser 10 ml/kg 05.27 ± 4.568 4.83 ± 2.790 4.97 ± 2.371 
Mianserin + Ser 1 mg/kg 82.62 ± 3.962*** 65.27 ± 5.982*** 56.63 ± 7.045*** 
3HF + Ser 25 mg/kg 48.05 ± 7.859** 37.27 ± 5.309* 28.92 ± 3.701  
50 mg/kg 59.64 ± 5.967*** 47.15 ± 5.907** 38.82 ± 6.172**  
75 mg/kg 75.28 ± 5.637*** 63.08 ± 4.049*** 51.81 ± 6.903*** 
Data is expressed as mean percent inflammation inhibition ± S.E.M *P < 0.05, **P < 0.01, ***P < 0.001 compared to vehicle plus Carrageenan (Carrag), histamine 
(His) or serotonin (Ser) treated group, one way ANOVA followed by Dunnett’ s post hoc test. 
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treatments on muscles and general body weakness. Treatment with 
standard gabapentin was linked with motor coordination impairment as 
evident by a decline in latency to fall in the gabapentin + paclitaxel 
treated animals. A significant effect on latency to fall in rotarod was 
observed [time= (F (4, 90) = 3.97, P < 0.0052, treatment= (F (5, 90) =
31.6, P < 0.0001, interaction= (F (20, 90) = 2.37, P < 0.0030)]. There 
was no motor coordination deficit observed in 3HF treated animals as 
compared to gabapentine treated group (Fig. 10). 
3.9. Effects of 3HF on mRNA expression of TNF-α, IL-1β, IL-6, CGRP, 
and substance P in the spinal cord 
To assess the anti-inflammatory and anti-neuropathic pain activities 
of 3HF, the expression of different cytokines, CGRP, and Substance P 
(SP) in the spinal cord was investigated through RT-PCR. Paclitaxel 
treated animals displayed an increase in the expression of these medi-
ators as compared to the vehicle-treated animals (P < 0.001). While 
3HF and gabapentin treated animals depicted reduced mRNA expression 
of these mediators in the spinal cord as compared to the vehicle treated 
animals (P < 0.001) (Fig. 11). 
3.10. Molecular docking studies 
In order to rationalize the binding mechanism of 3HF, the compound 
was subjected to molecular docking. For this purpose, initially, potential 
drug targets were searched via a systematic literature review (Kaur and 
Muthuraman, 2020). In our experiments, 3HF reduced the mRNA 
expression of several mediators including TNF-α, IL-1β, IL-6, CGRP, and 
Substance P in the spinal cord. Several studies have demonstrated the 
role of NF-κB in the underlying mechanism of inflammatory 
Fig. 5. Effect of 3HF on paclitaxel associated tactile allodynia. The symbol indicates mean PWT (g) ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 compared to 
paclitaxel + vehicle-treated group. ###P < 0.001 compared to the vehicle-treated group. Two-way ANOVA followed by Bonferroni test, n = 8 rats/group. 
Fig. 6. Effect of 3HF on paclitaxel-induced cold allodynia. The symbol indicates mean PWD (s) ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 compared to paclitaxel 
+ vehicle-treated group. ###P < 0.001 compared to the vehicle-treated group. Two-way ANOVA followed by Bonferroni test, n = 8 rats/group. 
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degenerative and neuropathic pain processes (Ahmed et al., 2019). 
Therefore, NF-κB was selected as a potential biological target for the 
docking of 3HF. Moreover, Substance P and CGRP are involved in nerve 
injury-induced neuropathic pain (Lee and Kim, 2007). CGRP exert its 
effects by binding with its receptor, so-called calcitonin receptor-like 
receptor (CALCRL), and a protein known as receptor 
activity-modifying protein (RAMP1), while substance P binds with its 
receptor known as neurokinin 1 receptor (NK1R) to mediate its 
biological effects. Both the receptors (CALCRL and NK1R) belong to the 
class of G-protein coupled receptors. CALCRL is composed of three 
subunits including RAMP1, calcitonin-like receptor (CLR) and receptor 
component protein (RCP). The CGRP binds with CALCRL in the com-
plex. In order to produce an effect, CGRP and CALCRL coincide with 
RAMP1 where the ligand-binding domain of CGRP is located. However, 
the antagonist and SP binding sites on the NK1R are present in the 
extracellular loops and transmembrane regions of NK-1R. Therefore, 
Fig. 7. Effect of 3HF on paclitaxel-induced thermal hyperalgesia in rats. The bar represents mean latency time in s ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 
compared to paclitaxel + vehicle-treated group. #P < 0.05, ##P < 0.01, ###P < 0.001 compared to the vehicle-treated group. . Two-way ANOVA followed by 
Bonferroni test, n = 8 rats/group. 
Fig. 8. Effect of 3HF on paclitaxel-induced tail heat-hyperalgesia in rats. The bar represents mean latency time in s ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, 
compared to paclitaxel + vehicle-treated group. #P < 0.05, ##P < 0.01, ###P < 0.001 compared to the vehicle-treated group. One-way ANOVA followed by 
Dunnett’s posthoc test, n = 8 rats/group. 
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3HF was also docked at the ligand-binding sites of the above-mentioned 
receptors. 
When the flavone docked at the binding site of NF-κB, and the –OH 
groups of 3HF mediated hydrogen bonds with the side chain of Lys 275 
and two water molecules in the DNA binding hinge region of NF-κB. The 
docking score of the compound was − 4.58, which is lesser than the 
docking scores of 3HF at Neurokinin 1 (NK1) and CGRP receptors. The 
binding interactions suggest that the 3HF has tendency to bind with the 
NF-κB, however, docking scores indicates that the binding potential of 
test compound towards NF-κB is lesser than the NK-1 and CGRP 
receptors. 
The docked orientation of 3HF at the NK-1 antagonist binding site 
revealed that the 3HF is nicely fitted at the binding groove and formed 
multiple hydrogen bonds with the surrounding residues including 
Lys181, Ile182 and Glu193. The flavone moiety of 3HF was stabilized by 
the hydrogen bonds donated by the backbone amino group and the side 
chain of Ile182 and Lys181, respectively. While the –OH group of 3HF 
donated a hydrogen bond to the side chain of Glu193. Moreover, 3HF 
depicted highly negative (− 5.36) docking score at NK-1 receptor, indi-
cating that this receptor could be a potential target for 3HF. 
Fig. 9. Effect of 3HF on paclitaxel-induced tail cold-hyperalgesia in rats. The bar represents mean latency time in s ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 
compared to paclitaxel + vehicle-treated group. ##P < 0.01, ###P < 0.001 compared to the vehicle-treated group. One-way ANOVA followed by Dunnett’s posthoc 
test, n = 8 rats/group. 
Fig. 10. Effect of 3HF on motor coordination in rats. The symbol indicates mean Latency to fall (s) ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 compared to 
paclitaxel + vehicle-treated group. Two-way ANOVA followed by Bonferroni test, n = 8 rats/group. 
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3HF was docked at the ligand-binding site located between the 
extracellular and transmembrane regions of CALCRL and RAMP1. At the 
ligand-binding site of the CGRP receptor, the 3HF produced good 
binding interactions. The –OH and the ring oxygen of 3HF interacted 
with the Lys 40 and Gln 202 of the receptor. Additionally, the side chain 
of Arg 18 of CGRP offered hydrophobic, particularly π-cation interaction 
to the ring moiety of the 3HF. The docked orientation of the 3HF at the 
CGRP-CGRP receptor interface showed that 3HF exhibit excellent 
binding potential, however, the docking score suggests that the 3HF has 
a lesser binding affinity towards CGRP-R as compared to NK-1 receptor. 
The docking scores and binding interactions of the 3HF with the selected 
drug targets are tabulated in Table 4. The docked view of the 3HF in the 
binding sites of the receptors is presented in Fig. 12. 
4. Discussion 
The anti-inflammatory activity of 3HF was tested in mice models of 
the different phlogistic agents (carrageenan, histamine, and serotonin) 
induced paw edema. The peripheral injection of carrageenan, histamine, 
and serotonin are associated with inflammation and pain (Naveed et al., 
2019). Thus, the anti-inflammatory potential of 3HF was tested in 
carrageenan, histamine, and serotonin-induced inflammatory mice 
models where 3HF produced significant inhibitory effects (Table 3). The 
results indicate that 3HF can serve as a potential candidate to inhibit 
inflammatory responses in vivo. Whereas the anti-nociceptive activities 
3HF was tested in writhing and hot plate tests. The finding of these 
activities indicated the anti-nociceptive potential of 3HF, which was 
further confirmed by naloxone antagonistic activity in hot plate test. 
Fig. 11. Effect of 3HF on; TNF-α mRNA expression level (A), IL-1β mRNA expression level. (B), IL-6 expression level (C), CGRP mRNA expression level (D), and 
Substance P (SP) mRNA expression level in the spinal cord of rats (E). The symbol indicates mean expression in arbitrary unit (A.U) ± SEM. *P < 0.05, **P < 0.01, 
***P < 0.001 compared to paclitaxel + vehicle-treated group. ##P < 0.01, ###P < 0.001 compared to the vehicle-treated group. One-way ANOVA followed by 
Dunnett’s posthoc test, n = 8 rats/group. 
Table 4 
The docking results of 3HF with the selected drug targets.  
S. No. Targets PDB ID Docking Score Binding Interactions 
Ligand Atoms Receptor Atoms Interactions Distance (Å) 
1 Nuclear factor kb 1NFK − 4.58 O3 NZ-LYS275 HBA 3.34 
O3 O–HOH377 HBA 2.89 
O2 O–HOH26 HBA 2.15 
2 Substance P Receptor (Neurokinin 1 receptor) 6HLP − 5.36 O2 OE2-GLU193 HBD 2.79 
O3 NZ-LYS181 HBA 3.34 
O3 N-ILE182 HBA 3.23 
3 CGRP Receptor 6E3Y − 5.11 O1 NZ-LYS40 HBA 3.01 
O2 NE2-GLN202 HBA 3.15 
6-ring NH2-ARG18 π-π 3.48 
HBA = Hydrogen bond acceptor, HBD = Hydrogen bond donor. 
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The anti-neuropathic effect of 3HF was tested in rat’s model of 
paclitaxel-induced peripheral neuropathy. Different neuropathic sensa-
tions like tactile and cold allodynia and heat-hyperalgesia were 
observed after the administration of paclitaxel. In connection to this 
study, effects of 3HF were studied on the expression of the inflammatory 
cytokines (TNF-α, IL-1β, IL-6), CGRP, and Substance P in the spinal cord. 
Pain management is crucially challenging specifically for patients 
suffering from chronic pain like neuropathic pain (Khan et al., 2016). 
Moreover, chemotherapy-induced-neuropathy is one of the major 
adverse effects of anti-cancer drugs which halts the effectiveness of 
existing cancer chemotherapy (Hur et al., 2019; Vitet et al., 2018). 
Paclitaxel-induced neuropathy is a well-known adverse effect in humans 
and rodents. Although, the onset of sign and symptoms of neuropathy 
depends on the accumulative dose, frequency, and time duration of the 
anticancer agent (Flatters and Bennett, 2004; Quasthoff and Hartung, 
2002). Although, Paclitaxel is the most effective and commonly used 
chemotherapeutic agent for the treatment of solid tumors, produces 
peripheral neurotoxicity linked with sensory abnormalities and neuro-
pathic pain during and after paclitaxel therapy (Flatters and Bennett, 
2004). Paclitaxel causes tactile- and cold-allodynia, and heat hyper-
algesia (Scripture et al., 2006). There is no effective treatment for 
chemotherapy-induced neuropathy. The gabapentinoids such as gaba-
pentin are used to treat neuropathic pain, however, their therapeutic 
efficacy is limited due to the occurrence of severe side effects such as 
somnolence, dizziness, lethargy, ataxia, and convulsions (Colloca et al., 
2017; Gilron et al., 2015). Gabapentin impairs motor coordination and 
balance after systemic administration (Ahmad et al., 2017b). In our 
findings, the test compound 3HF did not show any detectable motor 
Fig. 12. The binding modes of the compounds in three different selected targets are shown (A). The docked view of 3HF is shown in the DNA binding cavity of NF-κB 
(shown in the green and red ribbon), DNA is shown in the blue ribbon. Ligand is presented in a green stick model. Hydrogen bonds are shown in black lines (B). The 
docked orientation of the ligand in the extracellular ligand-binding domain of the NK-1 receptor is shown in the figure. Ligand and H-bonds are shown in green stick 
and black lines, respectively (C). The binding mode of the ligand is shown in the CGRP receptor. CGRP receptor (gold ribbon) is presented in complex with CGRP 
(blue ribbon) and receptor activity modifying protein 1 (red ribbon). Ligand and H-bonds are depicted in green stick model and black lines, respectively. 
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coordination deficit and found to be advantageous over gabapentin as a 
neurotherapeutic agent (Fig. 7). Similarly, 3HF produced beneficial ef-
fects in intensity to that produced by gabapentin. Gabapentinoids are 
effective for the treatment of peripheral neuropathies in 
paclitaxel-treated cancer patients (Aghili et al., 2019). 
Paclitaxel (4 mg/kg) was administered four times a week on alter-
nate days (1, 3, 5, and 7) to develop peripheral painful neuropathy. The 
pain behaviors were assessed by evaluating tactile allodynia, acetone 
induced cold allodynia, paw thermal hyperalgesia, tail hot and cold 
hyperalgesia on days 0, 2, 4, 8. In this study, 3HF (25, 50, and 75 mg/kg) 
possibly altered the nociceptive threshold in the form of different pain 
parameters like PWT (g) (Fig. 5), PWD (s) (Fig. 6), paw thermal 
hyperalgesia (PWL) (Fig. 7), tail withdrawal latency in hot and cold 
conditions (Figs. 8 and 9), in a dose-dependent manner. The 3HF treated 
animals possessed a significant anti-allodynic effect (tactile and acetone 
induced allodynia) by exhibiting increased PWT (g) and decreased PWD 
(s). Also, 3HF treated group showed a greater anti-hyperalgesic effect, 
increase PWL (s), and TWL (s), as compared to the paclitaxel treated 
group. The finding of the study demonstrated the anti-neuropathic po-
tential of 3HF is at the behavioral level. Therefore, the behavioral 
neurotherapeutic effect of 3HF was confirmed by investigating the ef-
fects of 3HF on the expression of key mediators of inflammation and 
pain such as cytokines (TNF-α, IL-1β, IL-6), CGRP and Substance P 
(Fig. 11). 
Inflammatory cytokines including TNF-α, IL-1β, and IL-6 play a vital 
role in dorsal root ganglia (DRG) and Spinal cord neuronal damage, 
involved in the nociceptive pathway sensitization (Ledeboer et al., 
2007), and in painful neuropathy. Paclitaxel induces the expression of 
proinflammatory cytokines in the rat DRG and spinal cord (Pavao-de--
Souza et al., 2012). In this study, paclitaxel treatment increased the level 
of proinflammatory cytokines in the spinal cord of rats. Several in vitro 
and in vivo studies revealed that proinflammatory cytokines contribute 
to the pathogenesis of pain (Khan et al., 2013). However, 3HF reduced 
the expression of these cytokines, therefore, 3HF may exert an anti-
nociceptive effect by reducing cytokines level in the spinal cord. 
In addition, the level of CGRP and Substance P was increased 
significantly in the superficial dorsal horn of paclitaxel treated rats. 
CGRP and Substance P are neurotransmitters involved in the patho-
genesis of neuropathic pain. These neurotransmitters released in the 
spinal dorsal horn by primary sensory afferents neurons contribute to 
production of allodynia and hyperalgesia (Ma and Eisenach, 2003). 
Treatment with 3HF attenuated the increased level of CGRP and Sub-
stance P significantly as compared to the paclitaxel treated rats. 
Structure based drug design is excelling the drug-discovery process 
and assists to study the mechanism of protein-ligand or drug-target 
binding (Halim et al., 2020; Ur Rehman et al., 2020). Therefore, the 
3HF was docked at the binding interface of receptors of CGRP and 
substance P, and NF-κB which is considered as the main mediator of 
inflammation. The 3HF showed excellent binding patterns with the 
entire selected drug target, however, binding potential for Substance P 
receptor was higher than the other targets. 
5. Conclusion 
In conclusion, the present study revealed that 3HF has ant- 
nociceptive, anti-inflammatory activity, and attenuative potential 
against paclitaxel-induced neuropathic painful conditions. The benefi-
cial effect of 3HF appears to occur via several mechanisms; including the 
inhibition of induction of cytokines (TNF-α, IL-1β, IL-6), CGRP, and 
substance P. 3HF is beneficial because of lack of central motor incoor-
dination adverse effects. Thus, our finding suggests that the 3HF might 
be a multi-targeted drug for the treatment of CIPN. In light of these 
results, 3HF could be developed for the management of CIPN. By mo-
lecular docking studies, it was elucidated that 3HF could inhibit the 
receptor of substance P effectively to execute its effect. However, more 
comprehensive studies are required to elucidate the detailed 
mechanistic role of the 3HF against neuropathic pain modalities. 
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